Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 5/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HSPA8 | P11142 | 3/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ATG7 | O95352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15746955 | 0.94 | HSPA5 (0.45) | HSPA5ADORA3HSPA8RXFP1CDK5 | |
| SCHEMBL18464494 | 0.90 | ADK (0.51) | HSPA5ADORA3HSPA8RXFP1CDK5 | |
| SCHEMBL22315144 | 0.87 | ADORA3 (0.51) | HSPA5ADORA3HSPA8RXFP1CDK5 | |
| SCHEMBL17918401 | 0.86 | HSPA8 (0.55) | HSPA5ADORA3HSPA8RXFP1CDK5 | |
| SCHEMBL18950207 | 0.85 | HSPA5 (0.43) | HSPA5ADORA3ATG7 | |
| SCHEMBL23114970 | 0.83 | HSPA8 (0.40) | HSPA5ADORA3HSPA8RXFP1CDK5 | |
| SCHEMBL14948817 | 0.79 | HSPA5 (0.42) | HSPA5ADORA3ATG7 | |
| SCHEMBL23906717 | 0.75 | HSPA5 (0.48) | HSPA5HSPA8RXFP1ATG7 | |
| SCHEMBL18852628 | 0.75 | ADK (0.43) | HSPA5ADORA3ATG7 | |
| SCHEMBL12369364 | 0.74 | ADORA3 (0.40) | ADORA3ATG7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828416-B2 | Modified polynucleotides for the production of secreted proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | HSPA5 1076/4885ADORA3 406/4885HSPA8 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.